0001104659-24-074873.txt : 20240625
0001104659-24-074873.hdr.sgml : 20240625
20240625210408
ACCESSION NUMBER: 0001104659-24-074873
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240624
FILED AS OF DATE: 20240625
DATE AS OF CHANGE: 20240625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HARTOUNIAN HARTOUN
CENTRAL INDEX KEY: 0001214476
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36641
FILM NUMBER: 241070404
MAIL ADDRESS:
STREET 1: 4264 CORTE FAVOR
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC.
CENTRAL INDEX KEY: 0001137883
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 207273918
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1325 AVENUE OF AMERICAS
STREET 2: 28TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: 201-488-0460
MAIL ADDRESS:
STREET 1: 1325 AVENUE OF AMERICAS
STREET 2: 28TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 20041122
FORMER COMPANY:
FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC
DATE OF NAME CHANGE: 20030827
FORMER COMPANY:
FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC
DATE OF NAME CHANGE: 20010409
4
1
tm2418256-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-06-24
0
0001137883
BRAINSTORM CELL THERAPEUTICS INC.
BCLI
0001214476
HARTOUNIAN HARTOUN
C/O BRAINSTORM CELL THERAPEUTICS INC.
1325 AVENUE OF THE AMERICAS 28TH FLOOR
NEW YORK
NY
10019
0
1
0
0
EVP, Chief Operating Officer
0
Common Stock
2024-06-24
4
A
0
30000
0
A
30000
D
Stock Option (Right to Buy)
0.38
2024-06-24
4
A
0
60000
0.00
A
2034-06-24
Common Stock
60000
60000
D
Represents shares of restricted stock units ("RSUs") awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The RSUs will vest in full on June 24, 2025, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.
The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on June 24, 2025, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.
/s/ Hartoun Hartounian
2024-06-25